TSI is developing a unique stroke therapeutic regimen modeled off of the natural, human thrombolytic system.  TSI’s stroke drug regimen induces rapid clot dissolution using significantly smaller, safer doses than is possible with drug monotherapy, the standard method of treatment today.

Thrombolysis is the biological defense against stroke and heart attacks. The natural human system uses two proteins, plasminogen activators, called tPA and prourokinase (proUK). These proteins bind to the surface of the occlusive clot in a specific order and trigger a cascade of events ending in the dissolution of the clot and the restoration of blood flow.

In the 1980s and 1990s, thanks to the development of biotechnology, several thrombolytic drugs were developed and used individually, as monotherapies.
It is time for a new-generation solution.